Payers taking steps to limit drug testing by programs

By  

ALCOHOLISM AND DRUG ABUSE WEEKLY, Vol. 27, Iss. 19, 2015-05 ,pp. : 5-6

John Wiley & Sons Inc

Access to resources Recommend Favorite

Women's uptake of non‐invasive DNA testing following a high‐risk screening test for trisomy 21 within a publicly funded healthcare system: findings from a retrospective review

By  

PRENATAL DIAGNOSIS, Vol. 35, Iss. 4, 2015-04 ,pp. : 342-347

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic screening, health care and the insurance industry: Should genetic information be made available to insurers?

By Ossa Diego   Towse Adrian  

The European Journal of Health Economics, Vol. 5, Iss. 2, 2004-05 ,pp. : 116-121

Springer Publishing Company

Access to resources Recommend Favorite

Genetic Testing and Private Insurance – A Case of “Selling One’s Body”?

By Hübner D.  

Medicine, Health Care and Philosophy, Vol. 9, Iss. 1, 2006-03 ,pp. : 43-55

Springer Publishing Company

Access to resources Recommend Favorite

Analysis of insurance preauthorization requests for BRCA1 and BRCA2 genetic testing: experience of the Humana Genetic Guidance Program

By Shah Amisha   Harris Heather   Brown Trisha   Graf Michael D   Sparks Leah   Mullins Tammy   Bruins Cari   Prewitt-Eddy Kira  

Personalized Medicine, Vol. 8, Iss. 5, 2011-09 ,pp. : 563-569

Future Medicine

Access to resources Recommend Favorite